Breast Cancer | Oncology Nursing News

Considerations for Treating Patients with CDK4/6 Inhibitors

BY PANELISTS: JOYCE OSHAUGHNESSY, MD; MICHAEL REFF, RPH, MBA; SARA M. TOLANEY, MD, MPH; LINDSAY SHAW, NP; KATE JEFFERS, PHARMD

CDK4/6 Inhibitors in Metastatic Breast Cancer
BY PANELISTS: JOYCE OSHAUGHNESSY, MD; MICHAEL REFF, RPH, MBA; SARA M. TOLANEY, MD, MPH; LINDSAY SHAW, NP; KATE JEFFERS, PHARMD

Benefits of PARP Inhibitor Use in Breast Cancer
BY JENNIFER LITTON, MD

Exercise During Adjuvant Breast Cancer Treatment Improves Cardiovascular Function
BY BETH FAND INCOLLINGO

Medically Integrated Pharmacy Teams Spur Innovations
BY PANELISTS: JOYCE OSHAUGHNESSY, MD; MICHAEL REFF, RPH, MBA; SARA M. TOLANEY, MD, MPH; LINDSAY SHAW, NP; KATE JEFFERS, PHARMD

Oral Oncolytics and Patient Adherence
BY PANELISTS: JOYCE OSHAUGHNESSY, MD; MICHAEL REFF, RPH, MBA; SARA M. TOLANEY, MD, MPH; LINDSAY SHAW, NP; KATE JEFFERS, PHARMD

Venetoclax Has Impressive Activity in ER+ and BCL-2+ Breast Cancer
BY WAYNE KUZNAR

Medically Integrated Dispensing Service Best Practices
BY PANELISTS: JOYCE OSHAUGHNESSY, MD; MICHAEL REFF, RPH, MBA; SARA M. TOLANEY, MD, MPH; LINDSAY SHAW, NP; KATE JEFFERS, PHARMD

Practical Challenges in Switching to CDK4/6 Inhibitors
BY PANELISTS: JOYCE OSHAUGHNESSY, MD; MICHAEL REFF, RPH, MBA; SARA M. TOLANEY, MD, MPH; LINDSAY SHAW, NP; KATE JEFFERS, PHARMD

Lumpectomy May Result in Better Quality of Life for Younger Patients than Mastectomy
BY KATIE KOSKO